新闻源 财富源

2019年10月17日 星期四

康缘药业(600557)公告正文

康缘药业:2014年第三季度报告

公告日期:2014-10-28

    江苏康缘药业股份有限公司(600557)                      2014 年第三季度报告
    股票简称:康缘药业                                         股票代码:600557
                 江苏康缘药业股份有限公司
                         600557
                        2014 年第三季度报告
                             二〇一四 年 十 月 二十七 日
                                         1 / 19
       江苏康缘药业股份有限公司(600557)                    2014 年第三季度报告
                                            目    录
    一、      重要提示......................................................... 3
    二、      公司主要财务数据和股东变化....................................... 3
    三、      重要事项......................................................... 5
    四、      附录............................................................. 8
                                             2 / 19
    江苏康缘药业股份有限公司(600557)                                           2014 年第三季度报告
    一、       重要提示1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整,不存在
    虚假记载、误导性陈述或者重大遗漏,并承担个别和连带的法律责任。1.2 公司全体董事出席董事会审议季度报告。1.3 公司负责人肖伟、主管会计工作负责人凌娅及会计机构负责人(会计主管人员)孙少敏保证季度报
    告中财务报表的真实、准确、完整。1.4 本公司第三季度报告未经审计。
    二、       公司主要财务数据和股东变化2.1 主要财务数据
                                                                              单位:元   币种:人民币
                                                                                 本报告期末比上年
                                      本报告期末              上年度末
                                                                                   度末增减(%)
    总资产                              3,693,109,469.69        3,432,193,654.33                    7.60
    归属于上市公司股东的净资产          2,079,079,972.51        1,878,957,313.47                   10.65
                                    年初至报告期末         上年初至上年报告        比上年同期增减
                                      (1-9 月)             期末(1-9 月)              (%)
    经营活动产生的现金流量净额                268,893,648.02      285,380,670.56                   -5.78
                                    年初至报告期末         上年初至上年报告        比上年同期增减
                                      (1-9 月)             期末(1-9 月)            (%)
    营业收入                            1,883,954,928.08        1,637,665,925.12                   15.04
    归属于上市公司股东的净利润                249,984,680.92      223,147,142.65                   12.03归属于上市公司股东的扣除非
                                          244,258,618.16      200,542,347.42                   21.80经常性损益的净利润
    加权平均净资产收益率(%)                         12.58                  13.10    减少 0.52 个百分点
    基本每股收益(元/股)                             0.501                  0.447                 12.08
    稀释每股收益(元/股)                             0.501                  0.447                 12.08
    公司于 2014 年 6 月实施完成《2013 年度利润分配方案》,总股本由 415,646,691 股变为 498,776,029股。根据《企业会计准则第 34 号—每股收益》应用指南的规定,本公司按照调整后的股本重新计算各列报期间的每股收益。扣除非经常性损益项目和金额
                                                 3 / 19
              江苏康缘药业股份有限公司(600557)                                                         2014 年第三季度报告
                                                                                                 单位:元        币种:人民币
                                                                    本期金额             年初至报告期末
                              项    目                                                                           说明
                                                                  (7-9 月)            金额(1-9 月)
         非流动资产处置损益                                             -63,056.65             -239,720.58
         计入当期损益的政府补助,但与公司正常经营
         业务密切相关,符合国家政策规定、按照一定                  5,077,242.00              10,214,742.00
         标准定额或定量持续享受的政府补助除外
         除上述各项之外的其他营业外收入和支出                       -466,699.52              -2,465,164.91
         所得税影响额                                               -720,279.57              -1,357,285.46
         少数股东权益影响额(税后)                                 -141,702.88                -426,508.29
                              合    计                             3,685,503.38              5,726,062.76
         2.2 截止报告期末的股东总数、前十名股东、前十名流通股东(或无限售条件股东)持股情况表
                                                                                                                     单位:股
    股东总数(户)                                                                                                           17,405
                                                     前十名股东持股情况
                                                                                                质押或冻结情况
           股东名称                 报告期          期末持       比例      持有有限售条
                                                                                               股份                  股东性质
           (全称)                 内增减          股数量        (%)       件股份数量                    数量
                                                                                               状态
                                                                                                                     境内非国有
    江苏康缘集团有限责任公司                     0    135,463,143    27.16      130,247,495         无         0
                                                                                                                        法人
    连云港康贝尔医疗器械有限公                                                                                           境内非国有
                                             0     26,558,806     5.32                   0     质押    26,400,000
    司                                                                                                                      法人
    肖伟                                         0     14,169,699     2.84                   0      无         0         境内自然人
    博时价值增长证券投资基金           -3,437,765       7,498,420     1.50                   0     未知                     其他中国银行-大成财富管理 2020
                                    7,187,057       7,187,057     1.44                   0     未知                     其他生命周期证券投资基金中国农业银行-长城安心回报
                                    1,102,143       7,102,177     1.42                   0     未知                     其他混合型证券投资基金中国银行股份有限公司-嘉实
                                    3,303,348       7,069,430     1.42                   0     未知                     其他研究精选股票型证券投资基金中国工商银行-中银持续增长
                                   -1,863,131       5,746,759     1.15                   0     未知                     其他股票型证券投资基金中国建设银行-长城消费增值
                                             0      5,400,000     1.08                   0     未知                     其他股票型证券投资基金中国民生银行股份有限公司-
    东方精选混合型开放式证券投                   0      4,833,513     0.97                   0     未知                     其他资基金
                                                 前十名无限售条件股东持股情况
                                                                                                           股份种类及数量
                        股东名称                                 持有无限售条件流通股的数量
                                                                                                          种类          数量
    连云港康贝尔医疗器械有限公司                                                         26,558,806       人民币普通股   26,558,806
                                                                4 / 19
            江苏康缘药业股份有限公司(600557)                                               2014 年第三季度报告
    肖伟                                                                         14,169,699   人民币普通股   14,169,699
    博时价值增长证券投资基金                                                      7,498,420   人民币普通股    7,498,420
    中国银行-大成财富管理 2020 生命周期证券投资基金                              7,187,057   人民币普通股    7,187,057
    中国农业银行-长城安心回报混合型证券投资基金                                  7,102,177   人民币普通股    7,102,177
    中国银行股份有限公司-嘉实研究精选股票型证券投资基金                          7,069,430   人民币普通股    7,069,430
    中国工商银行-中银持续增长股票型证券投资基金                                  5,746,759   人民币普通股    5,746,759
    中国建设银行-长城消费增值股票型证券投资基金                                  5,400,000   人民币普通股    5,400,000
    江苏康缘集团有限责任公司                                                      5,215,648   人民币普通股    5,215,648中国民生银行股份有限公司-东方精选混合型开放式证券投资
                                                                              4,833,513   人民币普通股    4,833,513基金
                                                          前十大股东中,江苏康缘集团有限责任公司和肖伟先生存在关联
                                                          关系,肖伟先生为江苏康缘集团有限责任公司第一大股东。公司
    上述股东关联关系或一致行动的说明                          未知其他股东之间、其他股东与前十名无限售条件股东之间是否
                                                          存在关联关系或一致行动人关系;公司未知前十名无限售条件股
                                                          东之间是否存在关联关系或一致行动人关系。
       三、     重要事项
       3.1 公司主要会计报表项目、财务指标重大变动的情况及原因
       √适用 □不适用
       截至报告期末,公司资产负债项目大幅变动的原因分析
          报表项目           期末余额              期初余额       变动比例                变动原因
                                                                              主要系报告期内公司研发合作预
       预付款项            53,354,187.56       34,809,699.35        53.27%
                                                                              付款项增多所致
                                                                              主要系报告期内公司项目投入增
       在建工程            341,227,408.99      228,847,446.36       49.11%
                                                                              加所致
       递延所得税资                                                           主要系报告期内所得税相关的递
                             4,386,612.33        6,607,770.32      -33.61%
       产                                                                     延资产减少所致
       其他非流动资                                                           主要系报告期内公司预付工程项
                           82,041,240.50       60,382,711.25        35.87%
       产                                                                     目及技术转让项目款项增多所致
                                                                              主要系报告期内公司销售收入增
       应交税费            80,167,345.43       53,443,259.38        50.00%
                                                                              长、利润增加所致
                                                                              主要系报告期内公司尚未支付完
       应付股利              3,101,935.96           446,055.40     595.41%
                                                                              控股股东现金红利款所致
       一年内到期的                                                           主要系报告期内公司归还项目贷
                             8,000,000.00      38,000,000.00       -78.95%
       非流动负债                                                             款所致
                                                                              主要系本报告期内本公积转增股
       资本公积            185,023,331.08      268,152,669.08      -31.00%
                                                                              本所致
                                                         5 / 19
      江苏康缘药业股份有限公司(600557)                                          2014 年第三季度报告利润表项目大幅动变动的原因分析
    报表项目         本期金额         上期金额       变动比例                 变动原因
                                                                   主要系报告期内公司贴现费用较去
    财务费用          53,390,154.81   37,726,473.44         41.52%
                                                                   年同期增加所致
                                                                   主要系子公司持有的可供出售金融
    投资收益              -1,030.95      416,024.45    -100.25%
                                                                   资产于去年同期到期所致
                                                                   主要系报告期内收到的政府补助减
    营业外收入        10,277,405.99   29,197,156.82     -64.80%
                                                                   少所致
    所得税费用        54,704,899.97   39,553,025.81         38.31%   主要系报告期内公司利润增加所致3.2 重要事项进展情况及其影响和解决方案的分析说明√适用 □不适用
    2013年1月18日,公司召开第四届董事会第二十二次会议,审议通过了《关于公司非公开发行股票方案的议案》和《关于公司非公开发行股票预案的议案》。(详见2013年1月21日刊登在《中国证券报》、《上海证券报》和上海证券交易所网站www.sse.com.cn的相关公告);
    2013 年 2 月 5 日,公司召开 2013 年第一次临时股东大会,审议通过了公司《关于公司非公开发行股票方案的议案》和《关于公司非公开发行股票预案的议案》。(详见 2013 年 2 月 6 日刊登在《中国证券报》、《上海证券报》和上海证券交易所网站 www.sse.com.cn 的相关公告);
    2013 年 12 月 12 日,公司召开第五届董事会第三次(临时)会议,审议通过了《关于公司非公开发行股票预案修订稿的议案》。(详见 2013 年 12 月 14 日刊登在《中国证券报》、《上海证券报》和上海证券交易所网站 www.sse.com.cn 的相关公告);2014 年 8 月 7 日,公司召开第五届董事会第六次(临时)会议,审议通过了《关于调整公司非公开发行股票方案的议案》。(详见 2014 年 8 月 9 日刊登在《中国证券报》、《上海证券报》和上海证券交易所网站 www.sse.com.cn 的相关公告);
    2014 年 8 月 25 日,公司召开 2014 年第一次临时股东大会审议《关于调整公司非公开发行股票方案的议案》、《关于修订公司非公开发行股票预案修订稿的议案》等。(详见 2014 年 8 月 26 日刊登在《中国证券报》、《上海证券报》和上海证券交易所网站 www.sse.com.cn 的相关公告);
    2014 年 10 月 22 日,中国证监会发行审核委员会对公司非公开发行 A 股股票的申请进行了审核。根据审核结果,公司本次非公开发行股票的申请获得审核通过。(详见 2014 年 10 月 23 日刊登在《中国证券报》、《上海证券报》和上海证券交易所网站 www.sse.com.cn 的相关公告)。3.3 公司及持股 5%以上的股东承诺事项履行情况√适用 □不适用
                                                                                                  是否
                                                                                         是否有
             承诺                                                           承诺时间              及时
    承诺背景            承诺方                   承诺内容                                    履行期
             类型                                                             及期限              严格
                                                                                           限
                                                                                                  履行
                                                 6 / 19
      江苏康缘药业股份有限公司(600557)                                       2014 年第三季度报告
                            公司控股股东江苏康缘集团有限责任公司在
                            与本公司签署的《避免同业竞争股东协议书》
                  江苏康
           解决             中郑重承诺:目前,公司所有业务,康缘集团
                  缘集团
           同业             及其控股和实际控制下的其他企业均不涉及。                   否      是
                  有限责
           竞争             康缘集团及其控股和实际控制下的其他企业
                  任公司
                            与本公司及本公司控股、实际控制的企业间不
                            存在同业竞争的情形。                     承诺时间
                            江苏康缘集团有限责任公司将尽量减少与本   为 2007 年与再融资
                            公司之间的关联交易。对于无法避免的任何业 7 月 10相关的承
                            务往来或交易均应按照公平、公允和等价有偿 日,本承
    诺
                            的原则进行,交易价格应按市场公认的合理价 诺长期有
                  江苏康
           解决             格确定,并按规定履行信息披露义务。康缘集 效
                  缘集团
           关联             团及其控股和实际控制下的其他企业与本公                     否      是
                  有限责
           交易             司及本公司控股和实际控制下的其他企业就
                  任公司
                            相互间关联事务及交易所做出的任何约定及
                            安排,均不妨碍对方为其自身利益、在市场同
                            等竞争条件下与任何第三方进行业务往来或
                            交易。3.4 执行新会计准则对合并财务报表的影响
    公司 2013 年度及 2014 年度 1-9 月份财务报表中关于长期股权投资、职工薪酬、财务报表列报、合并财务报表、公允价值计量、合营安排及与在其他主体中权益的相关业务及事项,按上述准则的规定进行核算与披露,本公司实施新准则无需要对公司财务报表进行追溯调整的事项,且不会对公司 2013 年度及 2014 年 1-9 月份报表项目金额产生影响。(详见 2014 年 10 月 28 日刊登在《中国证券报》、《上海证券报》和上海证券交易所网站 www.sse.com.cn 的相关公告)。
                                                  公司名称       江苏康缘药业股份有限公司
                                                  法定代表人                  肖伟
                                                  日期                 2014 年 10 月 27 日
                                              7 / 19
       江苏康缘药业股份有限公司(600557)                                           2014 年第三季度报告
    四、         附录
    4.1    财务报表
                                             合并资产负债表
                                            2014 年 9 月 30 日编制单位:江苏康缘药业股份有限公司
                                                          单位:元   币种:人民币    审计类型:未经审计
               项目                          期末余额                       年初余额流动资产:
      货币资金                                  205,129,943.29                     291,687,905.27
      结算备付金
      拆出资金
      交易性金融资产
      应收票据                                  435,486,238.11                     403,125,275.39
      应收账款                                  963,787,038.16                     827,633,824.29
      预付款项                                   53,354,187.56                     34,809,699.35
      应收保费
      应收分保账款
      应收分保合同准备金
      应收利息
      应收股利
      其他应收款                                 92,290,751.07                     73,206,950.95
      买入返售金融资产
      存货                                      104,266,749.20                     117,223,332.69
      一年内到期的非流动资产
      其他流动资产
        流动资产合计                         1,854,314,907.39                 1,747,686,987.94非流动资产:
      发放委托贷款及垫款
      可供出售金融资产
      持有至到期投资
      长期应收款
      长期股权投资                                3,976,346.70                       3,977,377.65
      投资性房地产
      固定资产                               1,123,982,553.13                 1,101,519,894.54
                                                 8 / 19
    江苏康缘药业股份有限公司(600557)                          2014 年第三季度报告
    在建工程                                 341,227,408.99     228,847,446.36
    工程物资
    固定资产清理
    生产性生物资产
    油气资产
    无形资产                                 181,661,486.50     181,830,660.96
    开发支出                                  42,182,051.29      42,000,000.00
    商誉                                      58,988,858.14      58,988,858.14
    长期待摊费用                                 348,004.72         351,947.17
    递延所得税资产                             4,386,612.33       6,607,770.32
    其他非流动资产                            82,041,240.50      60,382,711.25
      非流动资产合计                      1,838,794,562.30   1,684,506,666.39
          资产总计                        3,693,109,469.69   3,432,193,654.33流动负债:
    短期借款                                 676,000,000.00     655,000,000.00
    向中央银行借款
    吸收存款及同业存放
    拆入资金
    交易性金融负债
    应付票据                                  70,200,000.00      64,277,731.00
    应付账款                                 200,820,547.76     156,272,855.00
    预收款项                                  65,888,864.50      74,837,460.52
    卖出回购金融资产款
    应付手续费及佣金
    应付职工薪酬                               2,837,284.13       3,199,772.51
    应交税费                                  80,167,345.43      53,443,259.38
    应付利息                                   1,466,312.66       1,663,214.30
    应付股利                                   3,101,935.96         446,055.40
    其他应付款                               233,461,478.00     252,290,237.17
    应付分保账款
    保险合同准备金
    代理买卖证券款
    代理承销证券款
    一年内到期的非流动负债                     8,000,000.00      38,000,000.00
    其他流动负债                               9,484,909.29      10,462,200.00
                                             9 / 19
       江苏康缘药业股份有限公司(600557)                                 2014 年第三季度报告
        流动负债合计                        1,351,428,677.73          1,309,892,785.28非流动负债:
    长期借款                                  185,000,000.00            167,000,000.00
    应付债券
    长期应付款
    专项应付款                                  4,276,633.32              5,081,854.00
    预计负债
    递延所得税负债
    其他非流动负债                             15,523,889.88             15,673,889.88
        非流动负债合计                       204,800,523.20             187,755,743.88
          负债合计                          1,556,229,200.93          1,497,648,529.16所有者权益(或股东权益):
    实收资本(或股本)                        498,776,029.00            415,646,691.00
    资本公积                                  185,023,331.08            268,152,669.08
    减:库存股
    专项储备
    盈余公积                                  170,444,781.42            170,444,781.42
    一般风险准备
    未分配利润                              1,225,675,034.40          1,025,567,956.40
    外币报表折算差额                             -839,203.39               -854,784.43
    归属于母公司所有者权益
                                            2,079,079,972.51          1,878,957,313.47合计
    少数股东权益                               57,800,296.25             55,587,811.70
        所有者权益合计                      2,136,880,268.76          1,934,545,125.17
    负债和所有者权益总计                        3,693,109,469.69          3,432,193,654.33
    法定代表人:肖伟              主管会计工作负责人:凌娅       会计机构负责人:孙少敏
                                               10 / 19
    江苏康缘药业股份有限公司(600557)                                         2014 年第三季度报告
                                          母公司资产负债表
                                          2014 年 9 月 30 日编制单位:江苏康缘药业股份有限公司
                                                         单位:元   币种:人民币 审计类型:未经审计
             项目                          期末余额                       年初余额流动资产:
    货币资金                                  127,493,714.95                  179,653,677.73
    交易性金融资产
    应收票据                                  359,964,612.24                  315,367,271.31
    应收账款                                  836,734,981.95                  730,851,326.41
    预付款项                                   40,610,321.51                   25,909,218.78
    应收利息
    应收股利                                    1,914,732.34                    1,914,732.34
    其他应收款                                 66,541,614.96                   31,709,109.25
    存货                                       82,917,223.39                   98,376,261.52
    一年内到期的非流动资产
    其他流动资产
      流动资产合计                         1,516,177,201.34                 1,383,781,597.34非流动资产:
    可供出售金融资产
    持有至到期投资
    长期应收款
    长期股权投资                              191,352,542.37                  227,353,573.32
    投资性房地产
    固定资产                                  863,257,717.86                  832,806,032.90
    在建工程                                  328,128,633.73                  224,874,103.11
    工程物资
    固定资产清理
    生产性生物资产
    油气资产
    无形资产                                  131,814,765.50                  134,409,577.24
    开发支出                                   36,000,000.00                   36,000,000.00
    商誉
    长期待摊费用
    递延所得税资产                              2,632,213.67                    2,454,430.49
    其他非流动资产                             37,464,852.92                   22,693,983.67
                                               11 / 19
    江苏康缘药业股份有限公司(600557)                                  2014 年第三季度报告
      非流动资产合计                      1,590,650,726.05           1,480,591,700.73
        资产总计                          3,106,827,927.39           2,864,373,298.07流动负债:
    短期借款                                445,000,000.00             450,000,000.00
    交易性金融负债
    应付票据                                 70,200,000.00              50,000,000.00
    应付账款                                129,886,661.62              82,824,896.49
    预收款项                                 12,923,818.11              21,731,226.48
    应付职工薪酬                              1,683,360.91               1,298,598.26
    应交税费                                 71,151,372.21              40,542,830.03
    应付利息                                    967,720.14               1,144,707.36
    应付股利                                  2,655,880.56
    其他应付款                              143,803,629.99             168,428,674.28
    一年内到期的非流动负债                                              15,000,000.00
    其他流动负债                              7,184,909.29              10,462,200.00
      流动负债合计                         885,457,352.83              841,433,132.90非流动负债:
    长期借款                                165,000,000.00             165,000,000.00
    应付债券
    长期应付款
    专项应付款                                2,781,854.00               2,781,854.00
    预计负债
    递延所得税负债
    其他非流动负债
      非流动负债合计                       167,781,854.00              167,781,854.00
        负债合计                          1,053,239,206.83           1,009,214,986.90所有者权益(或股东权益):
    实收资本(或股本)                      498,776,029.00             415,646,691.00
    资本公积                                185,023,331.08             268,152,669.08
    减:库存股
    专项储备
    盈余公积                                168,637,620.86             168,637,620.86
    一般风险准备
    未分配利润                            1,201,151,739.62           1,002,721,330.23
    所有者权益(或股东权益)合计              2,053,588,720.56           1,855,158,311.17
    负债和所有者权益(或股东权            3,106,827,927.39               2,864,373,298.07
    法定代表人:肖伟
    益)总计                  主管会计工作负责人:凌娅           会计机构负责人:孙少敏
                                             12 / 19
           江苏康缘药业股份有限公司(600557)                                             2014 年第三季度报告
                                                  合并利润表
    编制单位:江苏康缘药业股份有限公司
                                                              单位:元    币种:人民币     审计类型:未经审计
                              本期金额           上期金额          年初至报告期期末        上年年初至报告期期
          项目
                              (7-9 月)         (7-9 月)          金额(1-9 月)          末金额(1-9 月)
    一、营业总收入              648,567,611.90      590,062,173.06     1,883,954,928.08          1,637,665,925.12
       其中:营业收入       648,567,611.90      590,062,173.06      1,883,954,928.08         1,637,665,925.12
             利息收入
             已赚保费
    手续费及佣金收入
    二、营业总成本              538,123,007.73      501,420,899.34     1,584,561,688.20          1,400,136,270.63
    其中:营业成本              163,200,935.59      149,635,081.44           487,734,796.77        419,418,347.62利息支出手续费及佣金支出退保金赔付支出净额提取保险合同准备金净额保单红利支出分保费用
    营业税金及附加               10,273,220.94        9,561,096.37           29,741,698.60          26,021,707.72
    销售费用                    283,872,348.01      249,503,005.23           787,931,897.70        685,489,604.56
    管理费用                     60,317,969.01       79,224,641.40       224,534,607.41            230,487,430.73
    财务费用                     19,932,563.37       12,951,051.88           53,390,154.81          37,726,473.44
    资产减值损失                     525,970.81         546,023.02             1,228,532.91             992,706.56加:公允价值变动收益(损失以“-”号填列)投资收益(损失以“-”
                                        0.00         72,642.12               -1,030.95              416,024.45号填列)其中:对联营企业和合
                                        0.00        -14,083.90               -1,030.95              -17,501.57营企业的投资收益汇兑收益(损失以“-”号填列)三、营业利润(亏损以
                            110,444,604.17       88,713,915.84       299,392,208.93            237,945,678.94“-”号填列)
    加:营业外收入                 5,111,112.00      18,244,996.12           10,277,405.99          29,197,156.82
                                                    13 / 19
           江苏康缘药业股份有限公司(600557)                                     2014 年第三季度报告
    减:营业外支出                   563,626.17       1,368,871.25     2,767,549.48           2,345,963.52其中:非流动资产处置损失四、利润总额(亏损总
                            114,992,090.00      105,590,040.71   306,902,065.44        264,796,872.24额以“-”号填列)
    减:所得税费用               25,116,812.05       15,891,102.87    54,704,899.97         39,553,025.81五、净利润(净亏损以
                             89,875,277.95       89,698,937.84   252,197,165.47        225,243,846.43“-”号填列)归属于母公司所有者
                             89,607,459.05       88,880,581.39   249,984,680.92        223,147,142.65的净利润
    少数股东损益                     267,818.90         818,356.45     2,212,484.55           2,096,703.78六、每股收益:(一)基本每股收益
                                       0.180             0.178            0.501                   0.447(元/股)(二)稀释每股收益
                                       0.180             0.178            0.501                   0.447(元/股)
    七、其他综合收益                  -3,114.68                           15,581.04
    八、综合收益总额             89,872,163.27       89,698,937.84   252,212,746.51        225,243,846.43归属于母公司所有者
                             89,604,344.37       88,880,581.39   250,000,261.96        223,147,142.65的综合收益总额归属于少数股东的综
                                 267,818.90         818,356.45     2,212,484.55           2,096,703.78合收益总额
       法定代表人:肖伟              主管会计工作负责人:凌娅        会计机构负责人:孙少敏
                                                    14 / 19
       江苏康缘药业股份有限公司(600557)                                         2014 年第三季度报告
                                              母公司利润表编制单位:江苏康缘药业股份有限公司
                                                      单位:元 币种:人民币 审计类型:未经审计
                              本期金额          上期金额      年初至报告期期末 上年年初至报告期
           项目
                              (7-9 月)        (7-9 月)      金额(1-9 月) 期末金额(1-9 月)
    一、营业收入               544,628,834.59     504,335,836.73   1,596,345,047.76    1,370,827,788.83
    减:营业成本               143,052,924.28     130,949,419.27     425,166,032.32       364,759,186.65
    营业税金及附加                8,379,425.66      7,940,960.66      25,079,285.86        21,544,273.05
    销售费用                   215,924,465.64     194,190,342.43     615,925,355.45       522,076,335.45
    管理费用                     49,682,381.84     71,515,121.67     191,864,916.59       197,014,735.24
    财务费用                     15,711,499.98     11,168,642.79      40,821,599.60        31,429,303.72
    资产减值损失                    591,870.33        545,993.34       1,185,221.20         1,044,335.60加:公允价值变动收益(损失以“-”号填列)投资收益(损失以“-”
                                                  -14,083.90         794,469.05           -17,501.57号填列)其中:对联营企业和合
                                       0.00       -14,083.90          -1,030.95           -17,501.57营企业的投资收益二、营业利润(亏损以
                           111,286,266.86      88,011,272.67    297,097,105.79        232,942,117.55“-”号填列)
    加:营业外收入                4,366,300.00     17,110,626.12       7,579,654.00        27,688,786.82
    减:营业外支出                  562,410.84      1,303,354.17       2,751,961.84         2,275,407.66其中:非流动资产处置损失三、利润总额(亏损总
                           115,090,156.02     103,818,544.62    301,924,797.95        258,355,496.71额以“-”号填列)
    减:所得税费用               25,680,591.97     15,490,882.69      53,616,785.64        38,464,935.56四、净利润(净亏损以
                            89,409,564.05      88,327,661.93    248,308,012.31        219,890,561.15“-”号填列)五、每股收益:(一)基本每股收益(元/股)(二)稀释每股收益(元/股)六、其他综合收益
    七、综合收益总额            89,409,564.05      88,327,661.93    248,308,012.31        219,890,561.15
    法定代表人:肖伟              主管会计工作负责人:凌娅           会计机构负责人:孙少敏
                                                 15 / 19
    江苏康缘药业股份有限公司(600557)                                         2014 年第三季度报告
                                          合并现金流量表
                                          2014 年 1—9 月编制单位:江苏康缘药业股份有限公司
                                                    单位:元   币种:人民币    审计类型:未经审计
                      项目                        年初至报告期期末金     上年年初至报告期期
                                                      额(1-9月)          末金额(1-9月)一、经营活动产生的现金流量:
    销售商品、提供劳务收到的现金                      1,977,378,283.57      1,873,422,731.76
    客户存款和同业存放款项净增加额
    向中央银行借款净增加额
    向其他金融机构拆入资金净增加额
    收到原保险合同保费取得的现金
    收到再保险业务现金净额
    保户储金及投资款净增加额
    处置交易性金融资产净增加额
    收取利息、手续费及佣金的现金
    拆入资金净增加额
    回购业务资金净增加额
    收到的税费返还                                           360,000.00            850,000.00
    收到其他与经营活动有关的现金                          88,751,693.14         51,628,296.24
      经营活动现金流入小计                          2,066,489,976.71       1,925,901,028.00
    购买商品、接受劳务支付的现金                         350,389,944.57        314,084,423.79
    客户贷款及垫款净增加额
    存放中央银行和同业款项净增加额
    支付原保险合同赔付款项的现金
    支付利息、手续费及佣金的现金
    支付保单红利的现金
    支付给职工以及为职工支付的现金                       248,246,068.71        209,877,972.32
    支付的各项税费                                       343,573,796.15        281,169,023.42
    支付其他与经营活动有关的现金                         855,386,519.26        835,388,937.91
      经营活动现金流出小计                          1,797,596,328.69       1,640,520,357.44
        经营活动产生的现金流量净额                      268,893,648.02        285,380,670.56二、投资活动产生的现金流量:
    收回投资收到的现金                                                          34,000,000.00
    取得投资收益收到的现金                                                         433,526.02
    处置固定资产、无形资产和其他长期资产收回
                                                          1,074,414.20             53,594.00的现金净额
                                              16 / 19
    江苏康缘药业股份有限公司(600557)                                         2014 年第三季度报告
    处置子公司及其他营业单位收到的现金净额                                        382,400.00
    收到其他与投资活动有关的现金
         投资活动现金流入小计                               1,074,414.20       34,869,520.02
    购建固定资产、无形资产和其他长期资产支付
                                                          279,623,427.21      262,292,297.57的现金
    投资支付的现金                                                             65,000,000.00
    质押贷款净增加额
    取得子公司及其他营业单位支付的现金净额
    支付其他与投资活动有关的现金                              177,530.70        7,966,504.82
         投资活动现金流出小计                            279,800,957.91       335,258,802.39
          投资活动产生的现金流量净额                     -278,726,543.71     -300,389,282.37三、筹资活动产生的现金流量:
    吸收投资收到的现金
    其中:子公司吸收少数股东投资收到的现金
    取得借款收到的现金                                    448,000,000.00      450,000,000.00
    发行债券收到的现金
    收到其他与筹资活动有关的现金
         筹资活动现金流入小计                            448,000,000.00       450,000,000.00
    偿还债务支付的现金                                    439,000,000.00      493,350,000.00
    分配股利、利润或偿付利息支付的现金                     82,409,049.57       49,472,743.65
    其中:子公司支付给少数股东的股利、利润
    支付其他与筹资活动有关的现金                                                5,530,217.50
         筹资活动现金流出小计                            521,409,049.57       548,352,961.15
          筹资活动产生的现金流量净额                     -73,409,049.57       -98,352,961.15
    四、汇率变动对现金及现金等价物的影响                           17,302.58          -56,185.14
    五、现金及现金等价物净增加额                              -83,224,642.68     -113,417,758.10
    加:期初现金及现金等价物余额                          288,354,585.97      342,150,797.10
    六、期末现金及现金等价物余额                              205,129,943.29      228,733,039.00
    法定代表人:肖伟              主管会计工作负责人:凌娅             会计机构负责人:孙少敏
                                               17 / 19
    江苏康缘药业股份有限公司(600557)                                           2014 年第三季度报告
                                          母公司现金流量表
                                            2014 年 1—9 月编制单位:江苏康缘药业股份有限公司
                                                     单位:元    币种:人民币    审计类型:未经审计
                      项目                         年初至报告期期末金      上年年初至报告期期
                                                       额(1-9月)           末金额(1-9月)一、经营活动产生的现金流量:
    销售商品、提供劳务收到的现金                      1,683,170,639.40       1,532,064,535.51
    收到的税费返还
    收到其他与经营活动有关的现金                           50,180,296.52         45,832,438.06
         经营活动现金流入小计                        1,733,350,935.92        1,577,896,973.57
    购买商品、接受劳务支付的现金                          300,027,929.65        265,618,414.43
    支付给职工以及为职工支付的现金                        188,509,211.69        158,526,565.60
    支付的各项税费                                        293,464,600.68        236,094,975.37
    支付其他与经营活动有关的现金                          657,302,973.37        683,861,874.66
         经营活动现金流出小计                        1,439,304,715.39        1,344,101,830.06
          经营活动产生的现金流量净额                     294,046,220.53         233,795,143.51二、投资活动产生的现金流量:
    收回投资收到的现金
    取得投资收益收到的现金
    处置固定资产、无形资产和其他长期资产收回
                                                            1,074,414.20             53,594.00的现金净额
    处置子公司及其他营业单位收到的现金净额                                          382,400.00
    收到其他与投资活动有关的现金
         投资活动现金流入小计                               1,074,414.20            435,994.00
    购建固定资产、无形资产和其他长期资产支付
                                                          255,282,196.34        232,939,926.45的现金
    投资支付的现金
    取得子公司及其他营业单位支付的现金净额
    支付其他与投资活动有关的现金
         投资活动现金流出小计                            255,282,196.34         232,939,926.45
          投资活动产生的现金流量净额                     -254,207,782.14      -232,503,932.45三、筹资活动产生的现金流量:
    吸收投资收到的现金
    取得借款收到的现金                                    248,000,000.00        263,000,000.00
    发行债券收到的现金
    收到其他与筹资活动有关的现金
                                               18 / 19
       江苏康缘药业股份有限公司(600557)                                      2014 年第三季度报告
        筹资活动现金流入小计                            248,000,000.00       263,000,000.00
      偿还债务支付的现金                                268,000,000.00       345,000,000.00
      分配股利、利润或偿付利息支付的现金                  69,948,401.17       45,169,996.63
      支付其他与筹资活动有关的现金
        筹资活动现金流出小计                            337,948,401.17       390,169,996.63
          筹资活动产生的现金流量净额                    -89,948,401.17      -127,169,996.63四、汇率变动对现金及现金等价物的影响
    五、现金及现金等价物净增加额                            -50,109,962.78      -125,878,785.57
      加:期初现金及现金等价物余额                      177,603,677.73       307,680,839.04
    六、期末现金及现金等价物余额                            127,493,714.95       181,802,053.47
    法定代表人:肖伟             主管会计工作负责人:凌娅            会计机构负责人:孙少敏
    4.2    审计报告若季度报告经过注册会计师审计,则附录应披露审计报告正文。□适用√不适用
                                              19 / 19